October 17, 2018 | Abattis Bioceuticals
VANCOUVER, BRITISH COLUMBIA / [October 17, 2018] / Abattis Bioceuticals Corp (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to celebrate the legalization of cannabis in Canada. This is a truly a newsworthy day in Canadian history, as we formally recognize the end of cannabis prohibition in our country. Abattis Bioceuticals is proud to recognize all of the activism, efforts and hard work completed by many Canadians throughout the years, culminating in this historical day.
Bill C-45, which legalizes the recreational use of cannabis in this country, was introduced on April 2017 and passed by the House of Commons seven months later. As Ottawa subsequently, decreed Legalization on Oct.17th, 2018 – Canada is now the second country in the world, and first G7 nation to legalize marijuana production, sale and consumption country-wide. Legalization is creating a whole new industry and the Company is very excited to be a part of this movement.
Abattis is moving forward in legalization, evolving continuously alongside the industry. Current highlights include the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation scheduled for public release on Cyber Monday (November 26, 2018), as well as continuing to build the Company’s foundation as a fully-integrated downstream service cannabis company, providing a wide range of products, as well as services including testing, growing, extraction, and infusion. Another major component of this evolution will continue to be in conjunction with the continued growth and development of Gabriola Green Farms (“Gabriola”), which the Company anticipates will be granted a license to produce (an “LP”) within the next year. With an LP, and together with the Company’s investments in health products (through Vergence Naturals Ltd.) and vaporizers (through Green Tree Therapeutics Inc.), the Company intends to continue to solidify connections with license holders. The Company will integrate its access to CBD and THC ingredients, to be added to current and upcoming products, enriching them through cannabinoid infused enhancements.
“We’re thrilled to recognize this momentous day in Canadian history” stated Robert Abenante, President and CEO of Abattis Bioceuticals. “This thriving new Canadian industry will increase future growth in Canada’s technology, marketplace, industry and job creation sectors. Canada has an opportunity to set the ‘global standard’ in crop production, cannabis science, product quality and patient care. Abattis Bioceuticals is optimistic about the future and plans to use our diverse interests in the cannabis space and strong financial position to take advantage of the continued growth in our industry” added Mr. Abenante
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to applicable laws of Canada and foreign jurisdictions.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,
Robert Abenante, President & CEO
For more information, please visit the Company’s website at: www.abattis.com
For inquiries please contact (808) 650-3007 or at email@example.com.
Abattis IR is managed by Canada One Communications Inc.
About Canada One Communications Inc.
Canada One is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One’s dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words including but not exclusive to “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release including the statement that the Company will release “Comfort” on Cyber Monday (November 26, 2018); the statement that the Company will continue to build its foundation as a fully-integrated downstream service cannabis company providing a wide range of products and services; the statement that Gabriola will be granted a production and cultivation license from Health Canada; the statement that the Company will integrate its access to CBD and THC to its current and upcoming products; the statement that the Company will experience continued growth in the future.
Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties including: that the Company will not release “Comfort” during the expected time or at all; that the Company will not receive the necessary regulatory approvals for its current or future products; that the Company will not see revenue growth at all or as anticipated; that the Company will not be well capitalized; that Gabriola will not be granted a production or cultivation license; that the Company will not be able to develop and supply a wide range of products and services to the market; that the Company’s investments will not produce significant revenue streams; that the Company’s investment initiatives will not drive growth; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control.
Additional risk factors are included in the Company’s filings, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.